Beraprost sodium, an orally active prostaglandin I2 analog, improves renal anemia in hemodialysis patients with peripheral arterial disease

Therapeutic Apheresis and Dialysis

Volumn 14, Issue 5, 2010, Pages 472-476

  Moriya, Hidekazu ^a   Ishioka, Kunihiro ^a   Honda, Kenjiro ^a   Oka, MacHiko ^a   Maesato, Kyoko ^a   Ikee, Ryota ^a   Hidaka, Sumi ^a   Ohtake, Takayasu ^a   Kobayashi, Shuzo ^a  

^a SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

Author keywords

Beraprost sodium; Hemodialysis; Peripheral arterial disease; Prostaglandin I2 analog; Renal anemia

Indexed keywords

BERAPROST; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; PROSTACYCLIN DERIVATIVE;

ADULT; AGED; ANEMIA; ANTIINFLAMMATORY ACTIVITY; ARTERY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANEMIA; EPOPROSTENOL; ERYTHROPOIETIN; FEMALE; FERRITINS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PROSPECTIVE STUDIES; RENAL DIALYSIS; VASODILATOR AGENTS;

EID: 77957364708     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2010.00814.x     Document Type: Conference Paper

References (24)

1. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976 263 : 663 665.
2. Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol 1995 75 : 3A 10A.
3. Libby P, Warner SJ, Friedman GB. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest 1998 81 : 487 498.
4. Panes J, Perry M, Granger DN. Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. Br J Pharmacol 1999 126 : 537 550. (Pubitemid 29087827)
5. Boxer LA, Allen JM, Schmidt M, Yoder M, Baehner RL. Inhibition of polymorphonuclear leukocyte adherence by prostacyclin. J Lab Clin Med 1980 95 : 672 678.
6. Kobayashi S, Moriya H, Ohtake T et al. Increased leukocyte aggregates are associated with atherosclerosis in patients with hemodialysis. Hemodial Int 2009 13 : 1 7.
7. Okamoto K, Ohtake T, Kobayashi S et al. Peripheral arterial occlusive disease is more prevalent in patients with hemodialysis: comparison with the findings of multidetector-row computed tomography. Am J Kidney Dis 2006 48 : 269 276.
8. Gejyo F, Saito A, Bessho M et al. Japanese Society for Dialysis Therapy. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial 2004 8 : 443 459.
9. 2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. J Immunol 2007 178 : 702 710. (Pubitemid 46095142)
10. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures properties and functions. Physiol Rev 1999 79 : 1193 1226.
11. Hertz R, Berman I, Keppler D, Bar-Tana J. Activation of gene transcription by prostacyclin analogues is mediated by the peroxisome- proliferators-activated receptor (PPAR). Eur J Biochem 1996 235 : 242 247.
12. Komhoff M, Lesener B, Nakao K, Seyberth HW, Nusing RM. Localization of the prostacyclin receptor in human kidney. Kidney Int 1998 54 : 1899 1908.
13. Yang T, Michele DE, Briggs JP et al. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol 1999 277 : F966 73.
14. Yokoyama C, Yabuki T, Tanabe T et al. Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation 2002 106 : 2397 2403.
15. Paller MS, Manivel JC. Prostaglandins protect kidneys against ischemic and toxic injury by a cellular effect. Kidney Int 1992 42 : 1345 1354.
16. Morham SG, Langenbach R, Smithies O et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995 83 : 473 482.
17. Hao CM, Redha R, Morrow J, Breyer MD. Peroxisome proliferator-activated receptor δ activation promotes cell survival following hypertonic stress. J Biol Chem 2002 277 : 21341 21345.
18. Hsu YH, Chen CH, Chen TH et al. Prostacyclin protects renal tubular cells from gentamicin-induced apoptosis via a PPARα-dependent pathway. Kidney Int 2008 73 : 578 587.
19. Hatae T, Wada M, Yokoyama C, Shimonishi M, Tanabe T. Prostacyclin- dependent apoptosis mediated by PPARδ. J Biol Chem 2001 276 : 46260 46267.
20. Guan Y. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol 2004 15 : 2801 2815.
21. Fisher JW, Radtke HW, Jubiz W, Nelson PK, Burdowski A. Prostaglandins activation of erythropoietin production and erythroid progenitor cells. Exp Hematol 1980 8 (Suppl 8 65 89.
22. Foley JE, Gross DM, Nelson PK, Fisher JW. The effects of arachidonic acid on erythropoietin production in exhypoxic polycythemic mice and the isolated perfused canine kidney. J Pharmacol Exp Ther 1978 207 : 402 409.
23. Fisher JW, Nelson PK, Belegu M, Hagiwara M, Beckman B. Prostanoid activation of erythropoiesis. Haematologia (Budap) 1984 17 : 137 149.
24. Fisher JW, Hagiwara M. Effects of prostaglandins on erythropoiesis. Blood Cells 1984 10 : 241 260.